Is GobyMeds legit and worth it?
GobyMeds is a real GLP-1 telehealth provider; we read its site and scored it 3.7/5 in our independent review (Competitive but Mixed). Biggest plus: Brand-name FDA-approved options. Watch-out: No lab testing.
Scorecard: strongest in Access (4.7/5) and Reputation (4.7/5); weakest in Authenticity (2.7/5) and Patient Protection (3.4/5).
Medications
Compounded Semaglutide, Compounded Tirzepatide, Zepbound, Wegovy (as listed on its site, 7 April 2026)
Monthly Cost
$99/mo compounded semaglutide; $133/mo compounded tirzepatide (as listed on its site, 7 April 2026)
Speed to Start
Fast
Prices and medications in this review are as listed on GobyMeds’s site on 7 April 2026, unless a line is marked otherwise, and have not been re-checked since. Note added 13 October 2026.
Corrected 14 October 2026: this review previously gave a Better Business Bureau rating or listing status. We kept no record of where it came from, so it has been removed. Trustpilot figures in this review are as recorded in April 2026 and have not been re-checked.
About GobyMeds
GoByMeds is one of the newest providers in our coverage, founded in 2023. Despite its youth, the platform has carved out a distinct niche by offering both compounded and brand-name GLP-1 medications, including Zepbound and Wegovy, at monthly costs between $99 and $133. This pricing structure is notably competitive for a provider that includes brand-name options — most competitors offering FDA-approved GLP-1s charge substantially more, making GoByMeds an outlier worth examining closely.
Early trust signals are positive. On Trustpilot, GoByMeds holds a 4.5 rating across 220+ reviews, a strong score for a company less than two years old. While the review volume is still modest compared to established players, the quality of early sentiment is encouraging and suggests GoByMeds is building a solid reputation from the ground up.
GoByMeds differentiates itself with starter bundles designed to reduce the friction of beginning GLP-1 therapy. These bundles typically include the initial consultation, first month of medication, and basic supplies at a single transparent price. For patients overwhelmed by the fragmented pricing models of many telehealth providers — where consultation fees, medication costs, shipping, and supplies are all itemized separately — the bundle approach simplifies the decision. The clinical support model is medium-tier, with standard provider check-ins and prescription management.
A standout feature is GoByMeds’ explicit PCOS support. Polycystic ovary syndrome affects an estimated 6-12% of women of reproductive age and is strongly associated with insulin resistance and weight gain. GLP-1 medications have shown particular promise for women with PCOS, and GoByMeds’ willingness to specifically market to and support this population indicates clinical awareness that goes beyond generic weight loss prescribing. For women with PCOS who have struggled to find providers who understand the hormonal complexity of their weight management challenges, this is a meaningful differentiator.
The primary concern with GoByMeds is its limited track record. A 2023 founding date means the company has less than two years of operational history, and the relatively small Trustpilot volume — while positive — does not yet provide the statistical confidence of a 5,000+ review dataset. The medium-support model also means patients needing intensive clinical oversight or nutrition coaching will need to supplement GoByMeds’ services independently. Still, the combination of accessible pricing, brand-name availability, and PCOS awareness makes GoByMeds a provider to watch as it matures.
At a Glance
Medications Offered
Compounded Semaglutide, Compounded Tirzepatide, Zepbound, Wegovy (as listed on its site, 7 April 2026)
Both
Cost & Insurance
- Monthly: $99/mo compounded semaglutide; $133/mo compounded tirzepatide (as listed on its site, 7 April 2026)
- 6-month estimate: $1,014-$2,994 (as listed on its site, 7 April 2026)
- Insurance: No
- Self-pay: Yes
Clinical Features
- Lab testing: No
- Dietitian access: No
- Pharmacies named: Not disclosed
Delivery & Access
- Format: Subcutaneous
- Nationwide telehealth: Yes
- Speed: Fast
- Spanish-speaking providers: Not stated Corrected 13 October 2026: this line said “Not available”, but our research had recorded it as unknown.
What the GobyMeds Intake Looks Like
We walked through GobyMeds’ GLP-1 weight-loss intake ourselves and came away with one of the most clinically thorough walkthroughs in our catalog. GobyMeds asks more named conditions, uses real phone OTP verification, and runs a $0-due hold-and-release payment model where the card is only charged if the licensed provider approves a prescription.
Among the strongest in the catalog. Eighteen named conditions in the Medical History multi-select, MEN-2 named explicitly alongside MTC personal-and-family history, anorexia/bulimia screened, gallbladder coverage in three states, and a named GLP-1 allergy multi-select listing six brand-and-INN combinations. Missing only validated mental-health and substance-use instruments.
Moderate. Account creation and a 6-digit phone OTP early in the flow add identity-assurance work, but the rest of the intake is clean: no fake-urgency timers, no marketing testimonial walls, and a $0-due-now checkout (a $299 hold is placed and only captured if approved). $99/month Starter Bundle pricing is on the low end of the catalog.
The 13 Stages
Clinical Safety Screens Performed
GobyMeds is one of the few platforms in our catalog that requires a true 6-digit SMS verification code before the medical profile begins — not just a phone-number-and-SMS-opt-in capture. The OTP raises the bar on identity assurance: the patient must control the device with the listed phone number, not merely type a number into a form. For a regulated medication category that ships nationwide, this is meaningfully better than the catalog norm of skipping verification entirely.
Unlike platforms that charge the first month upfront, GobyMeds places a $299 hold on the card at checkout that is captured only if the licensed provider approves the prescription. The patient owes $0 due now. The on-screen language is explicit: “You also agree to GobyMeds placing a ‘hold’ on your card for this amount. This hold will be fully released if you are not found medically eligible.” This aligns the platform’s incentive with patient eligibility — the company isn’t paid unless a clinician signs off, which puts it among the more patient-friendly checkouts we have walked.
No validated PHQ-2 or PHQ-9 mental-health instrument and no suicidality question. No substance or alcohol screen. No blood pressure or resting heart rate. No explicit pregnancy or breastfeeding screen (though the eating-disorder option captures part of the at-risk population). No diet or exercise history depth beyond the Body Metrics screen. No ID upload. The intake is exceptionally strong on FDA-black-box and endocrine-condition screening but does not cover the mental-health and substance-use dimensions that platforms like Hims, Ro, and LIV by WellNow include.
Source: GLP-1.Reviews editorial walkthrough on April 29, 2026. We completed every screen of the GobyMeds Weight Loss intake using a representative GLP-1 candidate persona and stopped before the $299 hold was authorized.
Opens gobymeds.com in a new tab. We may earn a commission if you start treatment through this link, at no additional cost to you.
Start your GLP-1 weight loss journey with GobyMeds today
Medical Disclaimer: This review is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs that should only be used under the supervision of a licensed healthcare provider. Individual results may vary.
Editorial Independence: GLP-1.Reviews maintains full editorial independence. We read providers’ own pages and public records and publish what we find, with the date we checked.
Corrected 13 October 2026: this review showed a “Verified Provider” badge and said our scores were “based on verified data and standardized criteria”. Neither described a check we had done, so both have been removed.
